Follow this page and receive
notifications about new suppliers
Boceprevir API Manufacturers
compare suppliers & get competitive offers
Date | Seller | Exporter country | Buyer | Importer country | Product | Quantity (KG) | Price per KG | Latest transactions |
|---|---|---|---|---|---|---|---|---|
| 01-Nov-2021 | (Hidden) | 
United States
| PRINCE SCI... | 
India
| BOCEPREVIR | No data available | $ @36$-7! | Check all data |
| 18-Jul-2020 | (Hidden) |
India
| CLEARSYNTH... | 
Canada
| CS-O-30873... | No data available | $ @36$-7! |
Filters
Reset current filters
Type
Production region
Qualifications
Country of origin
Producer
+ 0
All certificates
How does it work?
You can register for free as long as you are registering on behalf of a legal company related to the pharmaceutical industry
Search in the search bar the product that you’re looking for. We’ll show you an overview of all available suppliers. Use the filters to select the relevant suppliers only
Have you found interesting suppliers? Then it’s time to contact them. Use the send inquiry button and send them a message. You can send for each product, 3 inquiries per week
Suppliers get notified by Pharmaoffer that they’ve received a new inquiry. They will come back to you with their questions, certificates, and offer in the chat on Pharmaoffer. We will send you an email in case of any news
Does the supplier meet your quality and commercial requirements? Then you can place the order. Just follow the steps of our order module
Looking for Boceprevir API 394730-60-0?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Boceprevir. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Boceprevir
- Synonyms:
- Victrelis
- Cas Number:
- 394730-60-0
- DrugBank number:
- DB08873
- Unique Ingredient Identifier:
- 89BT58KELH
About Boceprevir
Here is a short description about Boceprevir. Boceprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients Treatment options for chronic Hepatitis C have advanced significantly since 20 with the development of Direct Acting Antivirals (DAAs) such as Boceprevir. Boceprevir is an inhibitor of NS3/4A, a serine protease enzyme, encoded by HCV genotypes 1 and 4 Synthesis.
These enzymes are essential for viral replication and serve to cleave the virally encoded polyprotein into mature proteins like NS4A, NS4B, NS5A and NS5B. The barrier for develoment of resistance to NS3/4A inhibitors is lower than that of NS5B inhibitors, another class of DAAs Subtitutions at amino acid positions 155, 156, or 168 are known to confer resistance. The substitutions of the enzyme's catalytic triad consisting of H58, D82, and S139 are also likely to alter the affinity of the drug for NS3/4A or the activity of the enzyme itself. Despite this disadvantage Boceprevir is still effective against HCV when paired with Ribavirin, Peginterferon alfa-2a, and Peginterferon alfa-2b.
Do you want to buy this product? Send an inquiry to the listed suppliers that meets your quality requirements.
Boceprevir is a type of Other Antiretrovirals
The category of Other Antiretrovirals falls under the broad umbrella of pharmaceutical Active Pharmaceutical Ingredients (APIs) used in the treatment of retroviral infections, including HIV. Other Antiretrovirals encompass a range of compounds that target various stages of the retroviral life cycle and provide alternative therapeutic options.
These APIs exhibit potent antiretroviral activity and are designed to combat drug-resistant strains of the virus, enhancing treatment efficacy. They work by inhibiting key enzymes involved in viral replication or by blocking viral entry into host cells.
One notable subcategory within Other Antiretrovirals is fusion inhibitors. These APIs prevent the fusion of the viral envelope with the host cell membrane, thereby inhibiting viral entry and subsequent infection. They target the viral protein gp41, which is crucial for fusion.
Another subcategory is integrase inhibitors, which hinder the action of the viral enzyme integrase. By doing so, they prevent the integration of viral DNA into the host cell genome, thus impeding viral replication and propagation.
Additionally, maturation inhibitors are included in this subcategory. These APIs interfere with the final stages of viral assembly and maturation, disrupting the production of infectious viral particles.
By expanding the repertoire of available antiretroviral options, Other Antiretrovirals play a vital role in the management of retroviral infections, especially when other treatment regimens have failed or become ineffective. Their development and utilization contribute to the advancement of HIV therapy and ultimately improve patient outcomes.
Boceprevir (Other Antiretrovirals), classified under Anti-infective Agents
Anti-infective agents are a vital category of pharmaceutical active pharmaceutical ingredients (APIs) used in the treatment of various infectious diseases. These agents play a crucial role in combating bacterial, viral, fungal, and parasitic infections. The demand for effective anti-infective APIs has grown significantly due to the increasing prevalence of drug-resistant microorganisms.
Anti-infective APIs encompass a wide range of substances, including antibiotics, antivirals, antifungals, and antiparasitics. Antibiotics are particularly important in fighting bacterial infections and are further categorized into different classes based on their mode of action and target bacteria. Antivirals are designed to inhibit viral replication and are essential in the treatment of viral infections such as influenza and HIV. Antifungals combat fungal infections, while antiparasitics are used to eliminate parasites that cause diseases like malaria and helminthiasis.
The development and production of high-quality anti-infective APIs require stringent manufacturing processes and adherence to regulatory standards. Pharmaceutical companies invest heavily in research and development to discover new and more effective anti-infective agents. Additionally, ensuring the safety, efficacy, and stability of these APIs is of utmost importance.
The global market for anti-infective APIs is driven by factors such as the rising incidence of infectious diseases, the emergence of new and drug-resistant pathogens, and the growing demand for improved healthcare infrastructure. Continuous advancements in pharmaceutical technology and the development of innovative drug delivery systems further contribute to the expansion of this market.
In conclusion, anti-infective agents are a critical category of pharmaceutical APIs that play a pivotal role in treating infectious diseases. Their effectiveness in combating various types of infections makes them essential components in the arsenal of modern medicine.
Boceprevir manufacturers | traders | suppliers
We have 1 companies offering Boceprevir produced in 1 different countries.
Get in contact with the supplier of your choice:
- Shanghai Acebright from China, product country of origin China
Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.
You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.
